The primary objective in this pilot study is to explore if asthma patients prescribed fixed
dose combinations (budenosid/formoterol (Symbicort®), salmeterol/fluticasone (Seretide®),
beclometasone/formoterol (Innovair®) are optimal treated regarding the mannitol challenge
test and the following reversibility test.
The primary endpoint is to identify asthma patients responding positive or negative to the
mannitol challenge test and/or the reversibility test.
The hypothesis is that not all patients are well treated.